newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

  • FDA accepted Cogent Biosciences' New Drug Application for bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM) & set a PDUFA target action date of June 29, 2027.
  • The FDA indicated no plan to hold an advisory committee meeting & identified no potential review issues for the AdvSM NDA.
  • NDA acceptance is supported by APEX pivotal trial data showing a 65% overall response rate, 81% pure pathological response rate, 79% 12-month progression-free survival, & 87% 12-month overall survival.
  • Cogent has NDAs for bezuclastinib under FDA review for NonAdvanced Systemic Mastocytosis (PDUFA date: December 30, 2026) & GIST (PDUFA date: November 30, 2026).
  • Active Expanded Access Programs are established for U.S. patients with SM or GIST who may benefit from bezuclastinib or the combination of bezuclastinib & sunitinib.
  • The Compensation Committee approved inducement equity awards to nine new employees, including 39,300 nonqualified options & 33,600 restricted stock units, pursuant to Nasdaq Listing Rule 5635(c)(4).